Weekly Fungal Diagnostics Research Update – 2 November 2026

New developments in molecular detection, laboratory identification and surveillance of medically important fungi

This week’s literature highlights the continuing development of molecular approaches to fungal diagnosis, alongside improvements in organism identification and targeted hospital surveillance.

A prospective study of Aspergillus droplet digital PCR provides important evidence on both assay selection and specimen processing. Other publications examine the application of microbial cell-free DNA testing to mucormycosis, sequencing-based diagnosis, and targeted screening for Candidozyma auris.

A recurring theme is the distinction between detecting fungal material and establishing clinically significant infection. Analytical sensitivity, specimen selection, diagnostic specificity and the availability of an appropriate reference standard remain central to evaluating new methods.

1. Droplet digital PCR for invasive aspergillosis: specimen selection is critical

Bitterman R et al. — Journal of Clinical Microbiology, 27 October 2026

This prospective, single-centre study evaluated Aspergillus droplet digital PCR (ddPCR) in patients with haematological malignancies undergoing bronchoscopy for pulmonary infiltrates. The investigators compared ddPCR in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC), with quantitative PCR (qPCR) as a comparator.

Among 203 participants, 26 met criteria for probable or proven invasive aspergillosis.

BALF supernatant ddPCR provided the best overall discrimination, with an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.80–0.96), sensitivity of 65% and specificity of 96%.

By comparison, BALF supernatant qPCR achieved sensitivity of 57% and specificity of 98%. Testing the BALF cell pellet was less sensitive than testing the supernatant.

The performance of EBC ddPCR was substantially poorer, with an AUC of 0.55 and specificity of only 45%. This does not support its use as a reliable non-invasive alternative in the population studied.

An important additional finding was the influence of prior antifungal treatment. In participants without recent mould-active antifungal exposure, BALF supernatant ddPCR achieved an AUC of 0.95, with sensitivity of 83% and specificity of 100%, although estimates were based on relatively few cases.

Diagnostic implications: The study supports further evaluation of ddPCR using BALF supernatant and reinforces the importance of specimen processing and antifungal exposure when interpreting molecular diagnostic performance. Its single-centre design, limited number of invasive aspergillosis cases and uncertainty around optimal positivity thresholds mean that external validation remains necessary.

Read the study

Download PDF

2. Plasma microbial cell-free DNA testing in pulmonary mucormycosis

Piepenbrink B et al. — IDCases, October 2026

This case report describes the use of plasma microbial cell-free DNA testing in the early diagnosis of pulmonary mucormycosis in a kidney transplant recipient.

Mucormycosis remains particularly challenging diagnostically because conventional culture may be insensitive, tissue sampling can be difficult in critically ill patients, and established circulating fungal biomarkers such as galactomannan and β-D-glucan are generally unsuitable for detecting Mucorales.

Plasma microbial cell-free DNA sequencing offers a potentially valuable complementary approach by detecting pathogen-derived nucleic acids without requiring direct sampling of an infected lesion.

Diagnostic implications: The report illustrates a clinically important application of non-invasive molecular testing in a high-risk transplant population. However, a single case cannot establish sensitivity, specificity or negative predictive value. Positive findings require interpretation alongside imaging, conventional microbiology, histopathology and the clinical presentation.

Read the study

3. Targeted Candidozyma auris admission surveillance using electronic health records

Alshahrani FS et al. — Infectious Diseases and Therapy / Infectious Drug Resistance, October 2026

A study from a Saudi tertiary hospital describes the implementation and diagnostic yield of an electronic health record-integrated risk-assessment pathway for targeted Candida auris (now Candidozyma auris) admission surveillance.

The approach addresses an increasingly important operational problem: identifying patients who should undergo screening for a healthcare-associated fungal pathogen capable of prolonged colonisation, environmental persistence and nosocomial transmission.

Integrating risk assessment into routine admission workflows may help standardise screening decisions and reduce reliance on individual clinician recognition of risk factors.

Diagnostic implications: This is primarily a surveillance and laboratory-service implementation study rather than an evaluation of a novel analytical assay. Its relevance lies in how diagnostic testing is targeted, requested and integrated into infection prevention. Screening yield, missed colonisation and the local epidemiological setting are essential considerations when assessing transferability to other hospitals.

Read the study

4. Candidozyma auris colonisation and infection surveillance in intensive care

Yiş R, Şenol G — International Microbiology, 29 October 2026

This study examines point prevalence and six-month colonisation–infection surveillance for Candidozyma auris in intensive care units.

The distinction between colonisation and invasive infection is especially important for C. auris. Colonised patients may contribute to transmission without having symptomatic disease, while invasive infection requires a different clinical response.

Diagnostic implications: Surveillance studies can inform screening frequency, sampling strategies and infection prevention policies. Their interpretation depends on the population screened, diagnostic methods used, and whether surveillance identifies previously unrecognised carriers or infections.

The paper is relevant to laboratories supporting intensive care and infection prevention teams, although its precise performance and yield figures require verification before incorporation into local screening recommendations.

Read the study

5. Combining conventional and sequencing-based approaches for unusual Mucorales infections

Tanida K et al. — Journal of Fungi, October 2026

A report of disseminated Mucor indicus infection in a heart transplant recipient examines the complementary roles of conventional and sequencing-based diagnostic approaches.

Uncommon Mucorales species can present identification challenges because reference databases and laboratory experience may be limited. Molecular methods can assist species-level identification, particularly when conventional phenotypic findings are inconclusive.

Diagnostic implications: The report reinforces the importance of maintaining access to specialist identification methods for unusual moulds. Sequencing can provide additional taxonomic resolution, but results must be considered alongside specimen quality, histopathological evidence of invasion and the clinical context.

As a case report, the findings are illustrative rather than evidence of comparative diagnostic superiority.

Read the study

6. Metagenomic versus targeted sequencing in lower respiratory tract infection

Zhao R et al. — Frontiers in Cellular and Infection Microbiology, October 2026

This retrospective cohort study compares metagenomic and targeted next-generation sequencing for pathogen detection in bronchoalveolar lavage fluid from patients with lower respiratory tract infections.

The comparison is relevant to fungal diagnostics because broad sequencing methods may identify fungi alongside bacterial and viral pathogens, while targeted approaches can offer different trade-offs in analytical sensitivity, cost and bioinformatic complexity.

Diagnostic implications: The central question is not simply which platform detects more organisms, but whether those detections improve clinical diagnosis. For respiratory fungal findings, distinguishing infection from colonisation or environmental contamination is essential.

The study is included as a broader molecular diagnostics development; fungal-specific diagnostic performance should be examined separately before drawing conclusions for clinical mycology.

Read the study

Research perspective

Three developments deserve particular attention from clinical mycology laboratories.

First, the Aspergillus ddPCR study provides useful comparative evidence and demonstrates that specimen selection may have as much influence on diagnostic performance as the molecular platform itself.

Second, emerging plasma cell-free DNA approaches offer a possible route to less-invasive diagnosis of difficult fungal infections, including mucormycosis. Their clinical value will depend on prospective validation and demonstration of added benefit over existing diagnostic pathways.

Third, C. auris surveillance research highlights the importance of diagnostic systems rather than assays alone. Effective identification of colonised patients depends on appropriate risk assessment, sampling and integration with infection prevention services.

Overall conclusion: Molecular diagnostics continue to expand the range of fungi that can be detected, but improvements in analytical detection must be accompanied by rigorous clinical validation. The strongest immediate evidence in this week’s selection concerns BALF supernatant ddPCR for invasive aspergillosis, while the remaining studies highlight important directions for further evaluation.